Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + oxaliplatin is a combination chemotherapy regimen widely used for the treatment of various advanced solid tumors, including non-small cell lung cancer, gallbladder cancer, urothelial carcinoma, and others. Gemcitabine is a synthetic pyrimidine nucleoside analog that inhibits DNA synthesis by being incorporated into DNA during replication and causing chain termination. Oxaliplatin is a third-generation platinum-based compound that forms crosslinks with DNA, inhibiting its replication and transcription and inducing apoptosis in tumor cells. The two drugs have distinct mechanisms of action but are both broad-spectrum cytotoxic agents; their toxicities do not overlap significantly, making the combination synergistic for antitumor activity[2][1][5]. This regimen is administered intravenously.
- Brand names
- EloxatinGemzar
- Other names
- 吉西他滨 + 奥沙利铂GemOx
02
Targets
DNA polymerase familyDNA
Beyond the preview
Go deeper on gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + oxaliplatin.